PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

Recruiting now · Phase 2/Phase 3

Conditions studied: Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer

In brief

This is a randomized trial evaluating the results of using of PARP inhibitor combined with angiogenesis inhibitor. in patients with homologous recombination deficient primary ovarian cancer, fallopian-tube cancer, or primary peritoneal cancer of the III-IV stages.

Key facts

Study ID

NCT07472140

Run by

N.N. Alexandrov National Cancer Centre

People needed

120

Starts

2025-07-01

Expected to finish

2033-06-30

Last updated by the study team

2026-03-16

Who can join

Age: 18 and older, up to 75. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18-≤75 years.
• Histologically confirmed diagnosis of serous or endometrioid high-grade ovarian cancer, fallopian-tube cancer or primary peritoneal cancer.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Possibility of performing diagnostic laparoscopy or cytoreductive surgery.
• Presence of homologous recombination deficiency (HRD).
• No contraindications to chemotherapy, or bevacizumab.
• Signed informed consent to participate in the study.

You may not qualify if…

• Presence of another active malignant invasive neoplasm.
• Pregnancy or lactation period.
• Disease progression during treatment.

Where it is running

• N.N. Alexandrov National Caner Centre — Minsk, Lesnoy, Belarus (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.